« Imclone's Secret Admirer |
| Why Don't You Just. . . »
September 26, 2008
I wrote back in the summer about the FDA's delayed decision on Lilly's potential anticoagulant blockbuster Effient (prasugrel). Well, those three months have zipped right by, and the agency is supposed to rule today.
Prediction, for what it's worth: I think the drug will be approved, but with label restrictions for the group(s) that seemed to respond best to it in trials - who may have been. at least partly, the groups that could put up with the associated bleeding the best, too. So no elderly patients, no low-weight ones, and no one with a history of stroke or TIA. That'll cut down the market for the drug, definitely, but not as much as if it doesn't get approved at all, right? I think the FDA will require Lilly to keep a careful eye on how Prasugrel performs in the real world while they wait on the results of the next trial to come in, with a possible label-language change to come at that point.
I'll give that option about a 70% chance. The 30% chance is that they delay things yet again, since the agency has been in a delaying risk-averse mood these days. We'll know soon. This new policy of not issuing those irritating "approvable" letters has made this sort of thing rather more tense, hasn't it?
+ TrackBacks (0) | Category: Cardiovascular Disease | Regulatory Affairs
POST A COMMENT
- RELATED ENTRIES
- Shire's Replagal Problems: An Inside Look?
- Bungled Structure, And How
- Roche Closes Nutley, Once Its US R&D Home
- The Next Five Years in the Drug Industry
- A Kinase Inhibitor Learns Something New
- The Good Ol' Friedel-Crafts
- Merck's Madagascar Marketing Mess
- Scientific Literacy: Where Do You Stop?